IL6 and COVID-19: Published trials with severe courses of COVID-19 reporting IL-6 levels were analyzed in a meta-analysis by Leisman et al., and the results were compared with studies including patients with COVID-19-independent conditions such as ARDS, sepsis, and CRS [140].